Last reviewed · How we verify

Lidocaine/Magnesium

University of Wisconsin, Madison · FDA-approved active Small molecule

Lidocaine blocks sodium channels to provide local anesthesia, while magnesium acts as a co-factor to enhance anesthetic efficacy and reduce pain signaling.

Lidocaine blocks sodium channels to provide local anesthesia, while magnesium acts as a co-factor to enhance anesthetic efficacy and reduce pain signaling. Used for Topical anesthesia and pain relief (specific indication not fully characterized in public literature).

At a glance

Generic nameLidocaine/Magnesium
SponsorUniversity of Wisconsin, Madison
Drug classLocal anesthetic combination
TargetVoltage-gated sodium channels; NMDA receptor
ModalitySmall molecule
Therapeutic areaPain management / Anesthesia
PhaseFDA-approved

Mechanism of action

Lidocaine is a local anesthetic that inhibits voltage-gated sodium channels in nerve fibers, preventing action potential propagation and blocking pain transmission. Magnesium potentiates this effect by modulating NMDA receptors and reducing neuronal excitability, enhancing the overall analgesic and anesthetic properties of the combination. This synergistic approach is used topically or locally to provide rapid pain relief.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: